MCK Stock Down Despite Latest Partnership to Boost SCD Treatment [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
by Vertex Pharmaceuticals Incorporated VRTX to expand commercial distribution options for CASGEVY. InspiroGene will partner with Vertex to expand distribution options for CASGEVY. CASGEVY (exagamglogene autotemcel), the first CRISPR-based gene-editing therapy approved by the FDA, is indicated for the treatment of patients 12 years and above with sickle cell disease (SCD) with recurrent vaso-occlusive crises or transfusion-dependent ß-thalassemia. The availability of the FDA-approved drug is expected to significantly solidify McKesson's foothold in the SCD treatment space. Following the announcement on Nov. 14, shares of the company lost nearly 0.6% till yesterday. Historically, the company has gained a high level of synergies from its various partnerships. Although the latest tie-up to expand commercial distribution options for VRTX's CASGEVY is likely to be beneficial for MCK's top-line growth going forward, the stock declined overall since the announcement despite a slight g
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Got $500? 1 Biotech Stock to Buy and Hold Forever [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 48% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/4/24 - Beat
VRTX
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/13/24 - Form 4
- VRTX's page on the SEC website